This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these template messages)
|
Formation | 2006 |
---|---|
Type | Charitable Organisation |
Headquarters | 5 Tanner St, London SE1 3LE |
Key people | Professor Anna Hemnes (President), Karen Osborn (CEO) |
Website | www.pvrinstitute.org |
The Pulmonary Vascular Research Institute (PVRI) is a global medical research charity. [1] It is registered Charity in the United Kingdom (Charity No: 1127115) and a private limited company by guarantee. The company registration number is 5780068. The PVRI is a professional membership organisation for doctors and scientists from around the world who have a special interest in pulmonary hypertension (PH) or pulmonary vascular diseases (PVD).
The concept of the PVRI as a research and educational institute catering to the global PVD community was initiated by Professor Ghazwan Butrous. The initial planning was conducted during a meeting at Heathrow, UK, with the key founders being Ghazwan Butrous, Stuart Rich, Martin Wilkins, Evangelos Michelakis, Marc Semigran, and Fritz Grimminger. In 2006, the organisation was formally established, and in 2007, it was registered as a charity in the UK. The PVRI commenced its operations with an inaugural meeting in Malta, attended by 25 PH professionals, who formed the framework of the organisation with the objective of mitigating the disease's global impact through study, instruction, and clinical care. The PVRI operates a virtual platform for networking between scientists and physicians, headquartered in the United Kingdom.
PVRI operations are governed by the PVRI Board of Directors. The executive branch comprises the President, who serves two-year terms, and the Chief Executive Officer, who is supported by administrative staff, and is responsible for overseeing the day-to-day operations of the PVRI. The PVRI has formed several "Task Forces," or specialised teams, to draw attention to particular PVDs.
It is generally understood that having high blood pressure can cause problems and reduce life expectancy. High blood pressure usually refers to the pressure in all the organs of the body, except for the lungs. It is very rare to find high blood pressure only in the lungs, but when it occurs, it is often deadly. This condition is called pulmonary hypertension, which leads to pulmonary vascular disease (PVD), the progressive obstruction of the lung blood vessels. This disease is incurable and often fatal. It often has a quiet and insidious onset and therefore the diagnosis is delayed, usually for about two years, by which time the patient is severely compromised. The sufferer gradually becomes short of breath and very tired, finds everyday activities exhausting and can no longer work or carry out everyday tasks. PVD affects all ages and social demographics across the globe. The heart has to work very hard to pump blood through the narrowed arteries in the lungs and eventually the patient develops severe heart failure. PVD can occur as a primary disorder, but there are also various factors which can contribute to PVD, such as living in high altitude, obesity, prolonged and strenuous exercise, congenital heart disease and various other causes.
It is estimated that over 60 million people in the world suffer from PVD, although this figure could be much higher as the disease is often undiagnosed or misdiagnosed.
The PVRI hosts two scientific meetings each year - the Annual Congress (held in January/February) and the Drug Discovery and Development Symposium (held in July). These meetings provide a forum for scientists and researchers in the field of pulmonary vascular disease, the pharmaceutical industry, and relevant regulatory authorities to determine which treatments should be developed for future use.
In addition to the two international scientific meetings, the PVRI Regional Task Forces organise local and national meetings to raise awareness of PVD. Additionally, the PVRI co-sponsors and supports a number of regional and worldwide events with the aim of advancing research and activities in the PVD field.
Members of the PVRI have access to an online library of clinical management guidelines, educational materials, advice, and information about current research initiatives and clinical trials.
Publications: the PVRI published its first periodical, the PVRI Review, in 2008-2011. The PVRI's official scientific journal, Pulmonary Circulation, is an international, peer-reviewed medical research journal that focuses exclusively on publishing original research, review articles, case reports, guidelines, and consensus articles in the fields of the pulmonary circulation and pulmonary vascular disease. In 2011, several PVRI members collaborated to produce the Textbook of Pulmonary Vascular Disease.
The PVRI's official scientific journal, Pulmonary Circulation , is an international, peer-reviewed medical research journal focused on publishing original research, review articles, case reports, guidelines and consensus articles exclusively in the fields of the pulmonary circulation and pulmonary vascular disease. It is published on behalf of the PVRI by Wiley.
In 2011, several PVRI members collaborated to produce the Textbook of Pulmonary Vascular Disease. [2]
The PVRI raises funds through membership contributions and fees to scientific events. Additionally, the PVRI receives grants from industry bodies and educational funds for its various initiatives.
The PVRI is currently involved in several significant initiatives, including the GoDeep meta-registry, the Papuca study, and the Innovative Drug Development Initiative (IDDI), where industry, academia, and clinicians collaborate to develop PH therapeutic outcomes quickly and safely.
Cardiology is the study of the heart. Cardiology is a branch of medicine that deals with disorders of the heart and the cardiovascular system. The field includes medical diagnosis and treatment of congenital heart defects, coronary artery disease, heart failure, valvular heart disease, and electrophysiology. Physicians who specialize in this field of medicine are called cardiologists, a sub-specialty of internal medicine. Pediatric cardiologists are pediatricians who specialize in cardiology. Physicians who specialize in cardiac surgery are called cardiothoracic surgeons or cardiac surgeons, a specialty of general surgery.
An artery is a blood vessel in humans and most other animals that takes oxygenated blood away from the heart in the systemic circulation to one or more parts of the body. Exceptions that carry deoxygenated blood are the pulmonary arteries in the pulmonary circulation that carry blood to the lungs for oxygenation, and the umbilical arteries in the fetal circulation that carry deoxygenated blood to the placenta. It consists of a multi-layered artery wall wrapped into a tube-shaped channel.
Blood pressure (BP) is the pressure of circulating blood against the walls of blood vessels. Most of this pressure results from the heart pumping blood through the circulatory system. When used without qualification, the term "blood pressure" refers to the pressure in a brachial artery, where it is most commonly measured. Blood pressure is usually expressed in terms of the systolic pressure over diastolic pressure in the cardiac cycle. It is measured in millimeters of mercury (mmHg) above the surrounding atmospheric pressure, or in kilopascals (kPa). The difference between the systolic and diastolic pressures is known as pulse pressure, while the average pressure during a cardiac cycle is known as mean arterial pressure.
Hypertension, also known as high blood pressure, is a long-term medical condition in which the blood pressure in the arteries is persistently elevated. High blood pressure usually does not cause symptoms itself. It is, however, a major risk factor for stroke, coronary artery disease, heart failure, atrial fibrillation, peripheral arterial disease, vision loss, chronic kidney disease, and dementia. Hypertension is a major cause of premature death worldwide.
Heart failure (HF), also known as congestive heart failure (CHF), is a syndrome caused by an impairment in the heart's ability to fill with and pump blood. Although symptoms vary based on which side of the heart is affected, HF typically presents with shortness of breath, excessive fatigue, and bilateral leg swelling. The severity of the heart failure is mainly decided based on ejection fraction and also measured by the severity of symptoms. Other conditions that have symptoms similar to heart failure include obesity, kidney failure, liver disease, anemia, and thyroid disease.
Pulmonary heart disease, also known as cor pulmonale, is the enlargement and failure of the right ventricle of the heart as a response to increased vascular resistance or high blood pressure in the lungs.
Pulmonary edema, also known as pulmonary congestion, is excessive fluid accumulation in the tissue or air spaces of the lungs. This leads to impaired gas exchange, most often leading to shortness of breath (dyspnea) which can progress to hypoxemia and respiratory failure. Pulmonary edema has multiple causes and is traditionally classified as cardiogenic or noncardiogenic.
A pulmonary artery is an artery in the pulmonary circulation that carries deoxygenated blood from the right side of the heart to the lungs. The largest pulmonary artery is the main pulmonary artery or pulmonary trunk from the heart, and the smallest ones are the arterioles, which lead to the capillaries that surround the pulmonary alveoli.
The American Heart Association (AHA) is a nonprofit organization in the United States that funds cardiovascular medical research, educates consumers on healthy living and fosters appropriate cardiac care in an effort to reduce disability and deaths caused by cardiovascular disease and stroke. They are known for publishing guidelines on cardiovascular disease and prevention, standards on basic life support, advanced cardiac life support (ACLS), pediatric advanced life support (PALS), and in 2014 issued the first guidelines for preventing strokes in women. The American Heart Association is also known for operating a number of highly visible public service campaigns starting in the 1970s, and also operates several fundraising events.
Pulmonary hypertension is a condition of increased blood pressure in the arteries of the lungs. Symptoms include shortness of breath, fainting, tiredness, chest pain, swelling of the legs, and a fast heartbeat. The condition may make it difficult to exercise. Onset is typically gradual. According to the definition at the 6th World Symposium of Pulmonary Hypertension in 2018, a patient is deemed to have pulmonary hypertension if the pulmonary mean arterial pressure is greater than 20mmHg at rest, revised down from a purely arbitrary 25mmHg, and pulmonary vascular resistance (PVR) greater than 3 Wood units.
The Fontan procedure or Fontan–Kreutzer procedure is a palliative surgical procedure used in children with univentricular hearts. It involves diverting the venous blood from the inferior vena cava (IVC) and superior vena cava (SVC) to the pulmonary arteries. The procedure varies for differing congenital heart pathologies. For example in tricuspid atresia, the procedure can be done where the blood does not pass through the morphologic right ventricle; i.e., the systemic and pulmonary circulations are placed in series with the functional single ventricle. Whereas in hypoplastic left heart syndrome, the heart is more reliant on the more functional right ventricle to provide blood flow to the systemic circulation. The procedure was initially performed in 1968 by Francis Fontan and Eugene Baudet from Bordeaux, France, published in 1971, simultaneously described in July 1971 by Guillermo Kreutzer from Buenos Aires, Argentina, presented at the Argentinean National Cardilogy meeting of that year and finally published in 1973.
Eisenmenger syndrome or Eisenmenger's syndrome is defined as the process in which a long-standing left-to-right cardiac shunt caused by a congenital heart defect causes pulmonary hypertension and eventual reversal of the shunt into a cyanotic right-to-left shunt. Because of the advent of fetal screening with echocardiography early in life, the incidence of heart defects progressing to Eisenmenger syndrome has decreased.
Endothelins are peptides with receptors and effects in many body organs. Endothelin constricts blood vessels and raises blood pressure. The endothelins are normally kept in balance by other mechanisms, but when overexpressed, they contribute to high blood pressure (hypertension), heart disease, and potentially other diseases.
A hypertensive emergency is very high blood pressure with potentially life-threatening symptoms and signs of acute damage to one or more organ systems. It is different from a hypertensive urgency by this additional evidence for impending irreversible hypertension-mediated organ damage (HMOD). Blood pressure is often above 200/120 mmHg, however there are no universally accepted cutoff values.
Vascular disease is a class of diseases of the vessels of the circulatory system in the body, including blood vessels – the arteries and veins, and the lymphatic vessels. Vascular disease is a subgroup of cardiovascular disease. Disorders in this vast network of blood and lymph vessels can cause a range of health problems that can sometimes become severe, and fatal. Coronary heart disease for example, is the leading cause of death for men and women in the United States.
The Dietary Approaches to Stop Hypertension or the DASH diet is a diet to control hypertension promoted by the U.S.-based National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services. The DASH diet is rich in fruits, vegetables, whole grains, and low-fat dairy foods. It includes meat, fish, poultry, nuts, and beans, and is limited in sugar-sweetened foods and beverages, red meat, and added fats. In addition to its effect on blood pressure, it is designed to be a well-balanced approach to eating for the general public. DASH is recommended by the United States Department of Agriculture (USDA) as a healthy eating plan. The DASH diet is one of three healthy diets recommended in the 2015–20 U.S. Dietary Guidelines, which also include the Mediterranean diet and a vegetarian diet. The American Heart Association (AHA) considers the DASH diet "specific and well-documented across age, sex and ethnically diverse groups."
Persistent fetal circulation is a condition caused by a failure in the systemic circulation and pulmonary circulation to convert from the antenatal circulation pattern to the "normal" pattern. Infants experience a high mean arterial pulmonary artery pressure and a high afterload at the right ventricle. This means that the heart is working against higher pressures, which makes it more difficult for the heart to pump blood.
Pulmonary rehabilitation, also known as respiratory rehabilitation, is an important part of the management and health maintenance of people with chronic respiratory disease who remain symptomatic or continue to have decreased function despite standard medical treatment. It is a broad therapeutic concept. It is defined by the American Thoracic Society and the European Respiratory Society as an evidence-based, multidisciplinary, and comprehensive intervention for patients with chronic respiratory diseases who are symptomatic and often have decreased daily life activities. In general, pulmonary rehabilitation refers to a series of services that are administered to patients of respiratory disease and their families, typically to attempt to improve the quality of life for the patient. Pulmonary rehabilitation may be carried out in a variety of settings, depending on the patient's needs, and may or may not include pharmacologic intervention.
Jason X.-J. Yuan is an American physician scientist whose research interests center on pulmonary vascular pathobiology and pulmonary hypertension. His current research is primarily focused on the pathogenic mechanisms of pulmonary vascular diseases and right heart failure.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a long-term disease caused by a blockage in the blood vessels that deliver blood from the heart to the lungs. These blockages cause increased resistance to flow in the pulmonary arterial tree which in turn leads to rise in pressure in these arteries. The blockages either result from organised blood clots that usually originate from the deep veins of the lower limbs of the body (thromboembolism) and lodge in the pulmonary arterial tree after passing through the right side of the heart. The blockages may also result from scar tissue that forms at the site where the clot has damaged the endothelial lining of the pulmonary arteries, causing permanent fibrous obstruction. Most patients have a combination of microvascular and macrovascular obstruction. Some patients may present with normal or near-normal pulmonary pressures at rest despite symptomatic disease. These patients are labelled as having chronic thromboembolic disease (CTED).